Jeffrey Bailey is listed as an executive officer and director on 5 SEC Form D filings by 2 issuers between Mar 2016 and Jun 2017: Euthymics Bioscience, Inc. (Cambridge, MA — biotechnology — 2017; $28M reported sold to 7 investors) and Neurovance, Inc. (Cambridge, MA — biotechnology — 2016–2017; $26.5M reported sold to 7 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director. Across those companies the filings report $54.5M sold in total.
All 2 issuers belong to the sponsor group Euthymics (3 issuers, $882K reported sold, 2010–2017).
What this means A sponsor group is one team that sets up a new company for each deal. Euthymics has 3 companies on file and $882K reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 4 bankruptcy cases matching the name listed in Key records below.
What this means 4 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 5 public filings for Jeffrey Bailey and found 8 differences: Jeffrey Bailey's role changed at Neurovance, Inc.: director → executive officer, director; Offering amount changed between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.